Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490169 | 0.93 | DHFR (0.87) | DHFRTYMS | |
| SCHEMBL7263046 | 0.93 | DHFR (0.87) | DHFRTYMS | |
| SCHEMBL9823269 | 0.91 | DHFR (1.00) | DHFRTYMS | |
| SCHEMBL18163402 | 0.89 | DHFR (0.80) | DHFRTYMS | |
| SCHEMBL9823412 | 0.89 | DHFR (1.00) | DHFRTYMS | |
| SCHEMBL14550680 | 0.87 | DHFR (0.79) | DHFRTYMS | |
| SCHEMBL9823099 | 0.87 | DHFR (0.78) | DHFRTYMS | |
| SCHEMBL9823187 | 0.87 | DHFR (0.81) | DHFRTYMS | |
| SCHEMBL9823192 | 0.87 | DHFR (0.81) | DHFRTYMS | |
| SCHEMBL9823716 | 0.87 | DHFR (0.81) | DHFRTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246314-A1 | Folate Receptor Binding Conjugates of Antifolates | PURDUE RESEARCH FOUNDATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-8546425-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| EP-0426666-A1 | SUBSTITUTED QUINAZOLINONES AS ANTICANCER AGENTS | WARNER-LAMBERT COMPANY (US) | 1991-05-15 | — | — | EP | disclosed |
| US-4857530-A | THYMIDYLATE SYNTHASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0316657-A1 | Substituted quinazolinones as anticancer agents | WARNER-LAMBERT COMPANY (US) | 1989-05-24 | — | — | EP | disclosed |
| WO-1989004307-A1 | SUBSTITUTED QUINAZOLINONES AS ANTICANCER AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246314-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | DHFR 3/4885TYMS 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.